Dexamethasone-suppression adrenal scintigraphy in hyperandrogenism: concise communication.
To assess the contribution of adrenal-derived androgens in women with hirsutism, adrenal scintigrams under dexamethasone suppression (DS) were performed on 35 women with increasing facial or body hair and irregular or absent menses. Based upon the DS regimen chosen (8 mg/d for 2 days or 4 mg/d for 7 days before the injection of 6 beta-[131I]iodomethylnorcholesterol), three imaging patterns were identified. The first was the absence of uptake before 3 days (8-mg DS) or before 5 days (4-mg DS) after injection. This imaging pattern was seen in 17 of the 35 patients studied and was considered normal. The second pattern was bilateral uptake earlier than 3 days (8-mg DS regimen) or 5 days (4-mg DS) after injection. This was seen in 13 of the 35 patients and was interpreted as bilateral early visualization. Adrenal-vein catheterization performed on six patients with this pattern showed increased adrenal-vein testosterone. The third pattern, observed in five patients, was unilateral early visualization, which in four cases investigated to date was the result of an adrenocortical adenoma. This study confirms the adrenal cortex as a source of androgens in women with hirsutism and hyperandrogenism and demonstrates the DS adrenal scintigraphy can be utilized to identify those women in whom adrenal-derived androgens contribute to their hyperandrogenism.
D000236:Adenoma / Q000000981:diagnostic imaging; D000293:Adolescent; D000302:Adrenal Cortex / Q000378:metabolism; D000306:Adrenal Cortex Neoplasms / Q000000981:diagnostic imaging; D000307:Adrenal Gland Diseases / Q000000981:diagnostic imaging; D000311:Adrenal Glands / Q000000981:diagnostic imaging; D000328:Adult; D000728:Androgens / Q000378:metabolism*; D003907:Dexamethasone; D005260:Female; D006628:Hirsutism / Q000000981:diagnostic imaging*; D006801:Humans; D011877:Radionuclide Imaging
D000728:Androgens; D003907:Dexamethasone